Relay Therapeutics Inc (NASDAQ: RLAY) kicked off on Friday, down -3.49% from the previous trading day, before settling in for the closing price of $3.73. Over the past 52 weeks, RLAY has traded in a range of $1.77-$10.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -23.05% over the past five years. While this was happening, its average annual earnings per share was recorded 20.84%. With a float of $129.32 million, this company’s outstanding shares have now reached $170.48 million.
Let’s look at the performance matrix of the company that is accounted for 261 employees. In terms of profitability, gross margin is -12.15%, operating margin of -4927.05%, and the pretax margin is -4341.53%.
Relay Therapeutics Inc (RLAY) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 24.61%, while institutional ownership is 84.20%. The most recent insider transaction that took place on Jul 09 ’25, was worth 219,123. In this transaction President and CEO of this company sold 61,379 shares at a rate of $3.57, taking the stock ownership to the 765,288 shares. Before that another transaction happened on Apr 30 ’25, when Company’s insider sold 10,739 for $3.00, making the entire transaction worth $32,217. This insider now owns 390,081 shares in total.
Relay Therapeutics Inc (RLAY) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.39% during the next five years compared to -23.05% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Take a look at Relay Therapeutics Inc’s (RLAY) current performance indicators. Last quarter, stock had a quick ratio of 19.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 80.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.23, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.85 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Relay Therapeutics Inc (NASDAQ: RLAY) saw its 5-day average volume 1.22 million, a negative change from its year-to-date volume of 2.21 million. As of the previous 9 days, the stock’s Stochastic %D was 74.78%.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 74.09%, which indicates a significant increase from 65.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.18 in the past 14 days, which was lower than the 0.25 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.22, while its 200-day Moving Average is $4.20. Nevertheless, the first resistance level for the watch stands at $3.68 in the near term. At $3.76, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.82. If the price goes on to break the first support level at $3.54, it is likely to go to the next support level at $3.48. The third support level lies at $3.40 if the price breaches the second support level.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
The company with the Market Capitalisation of 617.20 million has total of 171,445K Shares Outstanding. Its annual sales at the moment are 10,010 K in contrast with the sum of -337,710 K annual income. Company’s last quarter sales were recorded 7,680 K and last quarter income was -77,070 K.
